TNFRSF8 positive

Most patients (80%) received the BNT162b2 (Pfizer-BioNTech) vaccine...These findings support indeed the need for continued pharmacovigilance among clinicians, especially in patients with prior or latent lymphoproliferative conditions. Nevertheless, these extremely rare and indolent events should not alter the overall favourable risk-benefit profile of COVID-19 vaccination.

P=N/A, N=118, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2027 --> Jun 2026 | Trial primary completion date: May 2027 --> Jun 2026

P=N/A, N=100, Recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

P=N/A, N=118, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

The patient responded partially to cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) chemotherapy and achieved a complete metabolic response after second-line chemotherapy consisting of dexamethasone, high-dose cytarabine, and carboplatin (DHAC) followed by BEAM-ASCT consolidation. This case highlights diagnostic and therapeutic challenges in atypical presentations of PC-ALCL.

P2/3, N=370, Not yet recruiting, Polska Grupa Badawcza Chloniakow

The patient responded favorably to electron beam radiotherapy. This case underscores the importance of early biopsy in atypical or treatment-refractory ulcers and highlights the diagnostic relevance of recognizing rare variants such as the angiocentric subtype.

One patient was known to decease despite chemotherapy. In conclusion, oral manifestations of ALCL are very rare and more commonly represent a disseminated disease.

For multifocal or relapsed disease, brentuximab vedotin demonstrates the most robust prospective data and has reshaped the treatment landscape; however, alternative systemic therapies, including methotrexate and retinoids, remain relevant in selected patients. Overall, current management is supported largely by non-randomized data, and key gaps remain in risk stratification, optimal sequencing of therapies, and management of uncommon aggressive variants.

In the absence of alternative diagnostic patterns, these features raised suspicion for a cutaneous lymphoproliferative disorder, which was later confirmed by histopathological and immunohistochemical analyses. Our findings support the value of RCM as a practical tool in guiding differential diagnosis and biopsy, particularly for rapidly growing lesions located in anatomically sensitive areas.

Given the nonspecific clinical and radiological findings, anaplastic large cell lymphoma should be considered in the differential diagnosis of breast masses, particularly those associated with cystic changes or chronic inflammatory processes. Definitive diagnosis requires thorough histopathological and immunophenotypic evaluation.

P2, N=55, Recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027